This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

reputable news agency

proofread

CAR-T therapies not cost-effective for diffuse large B-cell lymphoma

CAR-T therapies not cost-effective for diffuse large B-cell lymphoma

For patients with diffuse large B-cell lymphoma (DLBCL), the chimeric antigen receptor T-cell therapies (CAR-T) axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) are not cost-effective, according to a study published online Dec. 5 in the Annals of Internal Medicine.

Amar H. Kelkar, M.D., M.P.H., from the Dana-Farber Cancer Institute in Boston, and colleagues examined the cost-effectiveness of second-line CAR-T versus salvage chemoimmunotherapy and consolidative autologous stem cell transplantation (ASCT) for treatment of DLBCL in a state transition microsimulation model. The target population was "high-risk" with DLBCL.

The researchers found that in the base-case analysis, the increase in was four and one months for axi-cel and liso-cel, respectively. The incremental cost-effectiveness ratio was $684,225 and $1,171,909, respectively, per quality-adjusted life year (QALY) for axi-cel and liso-cel; the corresponding incremental net monetary benefit was −$107,642 and −$102,477.

In sensitivity analysis, to be cost-effective with a willingness-to-pay threshold of $200,000 per QALY, the cost of CAR-T would need to be reduced to $321,123 and $313,730 for axi-cel and liso-cel, respectively. During a five-year period, implementation in would increase U.S. health care spending by about $6.8 billion.

"Moving CAR-T to the second line would have massive cost implications, but our results demonstrate that substantial price reduction could result in a cost-effective therapy," the authors write.

More information: Amar H. Kelkar et al, Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma, Annals of Internal Medicine (2023). DOI: 10.7326/M22-2276

Journal information: Annals of Internal Medicine

Copyright © 2023 HealthDay. All rights reserved.

Citation: CAR-T therapies not cost-effective for diffuse large B-cell lymphoma (2023, December 5) retrieved 17 April 2024 from https://medicalxpress.com/news/2023-12-car-t-therapies-cost-effective-diffuse-large.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

More evidence evolocumab exceeds cost-effectiveness

1 shares

Feedback to editors